Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1797058039579148288 |
|---|---|
| author | Iro, M Snape, M Voysey, M Jawad, S Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Dull, P Pollard, A European Men B Vaccine Study Group |
| author_facet | Iro, M Snape, M Voysey, M Jawad, S Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Dull, P Pollard, A European Men B Vaccine Study Group |
| author_sort | Iro, M |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T19:44:56Z |
| format | Journal article |
| id | oxford-uuid:21f6107b-5009-4c28-8b4f-86683b7029fb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:44:56Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:21f6107b-5009-4c28-8b4f-86683b7029fb2022-03-26T11:36:13ZCorrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:21f6107b-5009-4c28-8b4f-86683b7029fbEnglishSymplectic Elements at OxfordElsevier2017Iro, MSnape, MVoysey, MJawad, SFinn, AHeath, PBona, GEsposito, SDiez-Domingo, JPrymula, ROdueyungbo, AToneatto, DDull, PPollard, AEuropean Men B Vaccine Study Group |
| spellingShingle | Iro, M Snape, M Voysey, M Jawad, S Finn, A Heath, P Bona, G Esposito, S Diez-Domingo, J Prymula, R Odueyungbo, A Toneatto, D Dull, P Pollard, A European Men B Vaccine Study Group Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title | Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title_full | Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title_fullStr | Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title_full_unstemmed | Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title_short | Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. |
| title_sort | corrigendum to persistence of bactericidal antibodies following booster vaccination with 4cmenb at 12 18 or 24months and immunogenicity of a fifth dose administered at 4years of age a phase 3 extension to a randomised controlled trial vaccine 35 2017 395 402 |
| work_keys_str_mv | AT irom corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT snapem corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT voyseym corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT jawads corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT finna corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT heathp corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT bonag corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT espositos corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT diezdomingoj corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT prymular corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT odueyungboa corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT toneattod corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT dullp corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT pollarda corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 AT europeanmenbvaccinestudygroup corrigendumtopersistenceofbactericidalantibodiesfollowingboostervaccinationwith4cmenbat1218or24monthsandimmunogenicityofafifthdoseadministeredat4yearsofageaphase3extensiontoarandomisedcontrolledtrialvaccine352017395402 |